Nano Dimension (NNDM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Jun, 2026Executive summary
Murchinson Ltd. and affiliates, holding about 9% of shares, are soliciting proxies to enact significant governance changes at an extraordinary general meeting scheduled for July 31, 2026.
The solicitation seeks to amend the company's articles, remove and replace board members, and limit board powers regarding major transactions and shareholder rights plans.
Murchinson argues these changes are necessary to address underperformance, poor governance, and value-destructive decisions.
The proxy contest is being conducted independently of the current board and management, with Okapi Partners assisting in the solicitation.
Voting matters and shareholder proposals
Six proposals are on the agenda: a non-binding advisory vote on the strategic alternatives review, declassification of the board, requiring shareholder approval for rights plans and major transactions, removal of three directors, and appointment of three new nominees.
Murchinson recommends voting against the continuation of the strategic alternatives review and for all other proposals, including governance reforms and board changes.
Shareholders of record as of June 23, 2026, are eligible to vote, with each share entitled to one vote per proposal.
Board of directors and corporate governance
Proposal to declassify the board and require annual director elections to enhance accountability.
Proposal to remove three incumbent directors and appoint three new nominees with diverse backgrounds in real estate, finance, and IT.
Nominees have certified compliance with legal requirements and independence standards.
Latest events from Nano Dimension
- Revenue up 46% to $58.7M, Q2 margin 45.9%, net loss widens, cost cuts to reduce cash burn.NNDM
Q2 2026 - Shareholders face a pivotal vote on Board control, with future input on strategic transactions.NNDM
Proxy filing - Shareholders will vote on strategic direction, governance amendments, and board composition changes.NNDM
Proxy filing - Board supports strategic review and declassification, opposes governance and director changes.NNDM
Proxy filing - Proxy contest aims to declassify the board, restrict poison pills, and replace key directors.NNDM
Proxy filing - Proposed merger with Infinite Epigenetics offers a 20% premium and pivots to AI-powered diagnostics.NNDM
Proxy filing - $890M merger forms a Nasdaq-listed AI diagnostics leader targeting the $90–94B U.S. market.NNDM
M&A announcement - Q3 revenue surged 81% to $26.9M, but margins fell; Q4 guidance: $31.5M–$33.5M.NNDM
Q3 2025 - Record Q2 revenue, improved margins, and a transformative acquisition highlight best quarter.NNDM
Q2 2024